Table 3.
Clinical features of multiple myeloma patients and the expression of exosomal miRNAs in different groups.
| Characteristics | N (%) | let-7c-5p | p | let-7d-5p | p | miR-140-3p | p | miR-185-5p | p | miR-425-5p | p |
|---|---|---|---|---|---|---|---|---|---|---|---|
| (n = 48) | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | ||||||
| Age | 0.487 | 0.616 | 0.756 | 0.321 | 0.435 | ||||||
| ≥65 | 15 (31%) | 1.32 ± 0.91 | 1.22 ± 1.11 | 1.09 ± 1.04 | 1.56 ± 2.01 | 1.94 ± 1.11 | |||||
| <65 | 33 (69%) | 1.12 ± 0.84 | 1.06 ± 0.99 | 1.08 ± 0.96 | 0.98 ± 0.91 | 1.69 ± 0.58 | |||||
|
| |||||||||||
| Sex | 0.456 | 0.605 | 0.169 | 0.956 | 0.404 | ||||||
| Male | 22 (46%) | 1.32 ± 1.01 | 1.23 ± 1.22 | 0.86 ± 0.91 | 1.34 ± 1.73 | 0.67 ± 0.67 | |||||
| Female | 26 (54%) | 1.06 ± 0.71 | 1.00 ± 0.82 | 1.15 ± 1.02 | 0.99 ± 0.92 | 0.86 ± 0.86 | |||||
|
| |||||||||||
| Heavy chain | 0.479 | 0.505 | 0.266 | 0.501 | 0.101 | ||||||
| No expression | 15 (31%) | 1.02 ± 0.62 | 1.29 ± 0.67 | 1.03 ± 0.66 | 0.81 ± 0.72 | 0.59 ± 0.67 | |||||
| IgG | 16 (34%) | 1.27 ± 0.87 | 1.29 ± 1.23 | 1.04 ± 0.68 | 1.11 ± 0.88 | 0.66 ± 0.39 | |||||
| IgA | 13 (27%) | 1.37 ± 0.95 | 1.16 ± 1.12 | 1.34 ± 1.38 | 1.81 ± 2.21 | 1.26 ± 1.14 | |||||
| IgD | 4 (8%) | 0.83 ± 0.48 | 0.83 ± 0.47 | 0.50 ± 0.45 | 0.64 ± 0.86 | 0.46 ± 0.64 | |||||
|
| |||||||||||
| Light chain | 0.805 | 0.846 | 0.366 | 0.568 | 0.595 | ||||||
| Nonsecretion | 1 (2%) | — | — | — | — | — | |||||
| Κ | 27 (56%) | 1.10 ± 0.72 | 0.97 ± 0.68 | 0.96 ± 0.68 | 0.96 ± 0.75 | 0.75 ± 0.75 | |||||
| Λ | 20 (42%) | 1.24 ± 1.02 | 1.26 ± 0.1.36 | 0.99 ± 1.21 | 1.36 ± 0.1.81 | 0.73 ± 0.74 | |||||
|
| |||||||||||
| D-S stage | 0.840 | 0.852 | 0.444 | 0.940 | 0.882 | ||||||
| I | 7 (15%) | 1.19 ± 0.79 | 1.06 ± 0.74 | 0.93 ± 0.63 | 0.83 ± 0.67 | 1.10 ± 1.30 | |||||
| II | 2 (4%) | 1.11 ± 0.07 | 0.89 ± 0.03 | 1.31 ± 0.00 | 0.79 ± 0.25 | 0.60 ± 0.19 | |||||
| III | 39 (81%) | 1.19 ± 0.90 | 1.13 ± 1.09 | 1.02 ± 1.05 | 1.12 ± 1.45 | 0.78 ± 0.68 | |||||
|
| |||||||||||
| ISS stage | 0.047 ∗ | 0.055 | 0.083 | 0.072 | 0.027 ∗ | ||||||
| I | 7 (15%) | 1.91 ± 0.92 | 1.69 ± 0.79 | 1.61 ± 1.00 | 1.55 ± 1.02 | 1.63 ± 1.25 | |||||
| II | 11 (23%) | 1.03 ± 0.76 | 0.92 ± 0.75 | 0.81 ± 0.58 | 1.43 ± 0.98 | 0.67 ± 0.47 | |||||
| III | 30 (62%) | 1.07 ± 0.82 | 1.04 ± 1.12 | 0.94 ± 1.05 | 0.98 ± 1.43 | 0.60 ± 0.60 | |||||
|
| |||||||||||
| Renal damage | 0.066 | 0.011 ∗ | 0.002 ∗ | 0.026 ∗ | 0.010 ∗ | ||||||
| Yes | 12 (25%) | 0.79 ± 0.74 | 0.64 ± 0.49 | 0.28 ± 0.27 | 0.37 ± 0.42 | 0.26 ± 0.19 | |||||
| No | 36 (75%) | 1.32 ± 0.86 | 1.27 ± 0.1.10 | 1.27 ± 1.00 | 1.40 ± 1.45 | 0.93 ± 0.84 | |||||
ISS, International Staging System; ∗p < 0.05.